[{"id":"0e136b5e-db43-41d6-9dbc-e487bfbe2822","acronym":"","url":"https://clinicaltrials.gov/study/NCT03825718","created_at":"2021-01-18T18:53:39.691Z","updated_at":"2025-02-25T15:08:17.270Z","phase":"Phase 1","brief_title":"A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT03825718","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC007F • S1904"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2022-04-28"},{"id":"91151d5d-4ac8-4997-9821-89c52c8e7599","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572308","created_at":"2021-01-18T21:49:55.166Z","updated_at":"2024-07-02T16:36:28.570Z","phase":"Phase 1","brief_title":"Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells","source_id_and_acronym":"NCT04572308","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • CD7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • SENL101"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 05/30/2021","primary_completion_date":" 05/30/2021","study_txt":" Completion: 05/30/2021","study_completion_date":" 05/30/2021","last_update_posted":"2021-06-29"},{"id":"95beae3b-8f0c-4d74-87ac-938908f3ca15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792593","created_at":"2021-03-11T12:53:43.576Z","updated_at":"2024-07-02T16:36:33.425Z","phase":"","brief_title":"Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04792593","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • CD7","pipe":" | ","alterations":" CD19 positive","tags":["IFNG • IL6 • TNFA • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl-h19"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 12/10/2021","primary_completion_date":" 12/10/2021","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2021-03-11"},{"id":"1c46647b-3ee2-489b-b3d5-6f10948818ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447547","created_at":"2021-01-18T21:24:04.198Z","updated_at":"2024-07-02T16:36:40.582Z","phase":"","brief_title":"Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04447547","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD19 • IFNG • IL6 • TNFA • IL10","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl 1904B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-09-29"},{"id":"adf97ffe-a5ab-4c9c-b219-b9ac297c59f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447573","created_at":"2021-01-18T21:24:04.628Z","updated_at":"2024-07-02T16:36:40.602Z","phase":"","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04447573","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • senl_BCMA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-09-29"},{"id":"0edb6ef9-4150-443b-8df9-568ab5c5b766","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546893","created_at":"2021-01-18T21:45:01.127Z","updated_at":"2024-07-02T16:36:41.067Z","phase":"","brief_title":"Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia","source_id_and_acronym":"NCT04546893","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10","pipe":" | ","alterations":" CD19 positive","tags":["IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl 1904B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-09-14"},{"id":"2a21b70e-502b-4d34-849c-e7ccf37ca4dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546906","created_at":"2021-01-18T21:45:01.405Z","updated_at":"2024-07-02T16:36:41.044Z","phase":"","brief_title":"Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04546906","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • CD22 • IL10","pipe":" | ","alterations":" CD22 positive","tags":["IFNG • IL6 • TNFA • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl_22"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-09-14"},{"id":"35cdc032-29a6-4e99-a7d5-d2b3f5f5832a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412174","created_at":"2021-01-18T21:16:18.074Z","updated_at":"2025-02-25T14:59:08.827Z","phase":"Phase 1","brief_title":"A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL","source_id_and_acronym":"NCT04412174","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-06-02"},{"id":"af265f1e-7c8e-4e79-a08b-c9b1dc9436b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129099","created_at":"2021-01-18T20:10:19.366Z","updated_at":"2025-02-25T15:08:51.386Z","phase":"Phase 1","brief_title":"A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT04129099","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-05-28"},{"id":"e019301d-43b0-4220-a310-76474b03ce88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03825731","created_at":"2021-01-18T18:53:39.912Z","updated_at":"2025-02-25T15:08:17.722Z","phase":"Phase 1","brief_title":"A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT03825731","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/16/2019","primary_completion_date":" 09/16/2019","study_txt":" Completion: 09/16/2019","study_completion_date":" 09/16/2019","last_update_posted":"2019-01-31"}]